An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Phase 3
280
about 4 years
18–65
79 sites in AR, AZ, CA +20
What this study is about
Researchers are testing the safety and tolerability of a treatment called KarXT, which contains xanomeline and trospium chloride, for people with schizophrenia who haven't responded well to their current medication. The trial will last 1473 days and involve about 280 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Xanomeline and Trospium Chloride Capsules
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
trospium, Antipsychotic Agent [TC] (Cholinergic Muscarinic Agonists)
oral
Primary: Incidence of treatment-emergent adverse events (TEAEs)
Secondary: Incidence of TEAEs leading to discontinuation of study drug, Incidence of serious treatment-emergent adverse events (TEAEs)
Psychiatry / Mental Health